https://www.selleckchem.com/pr....oducts/jnk-inhibitor
We aimed to evaluate the efficacy and safety of nanoparticle albumin-bound (nab-) paclitaxel for previously treated patients with advanced NSCLC. In this randomized, open-label, noninferiority phase 3 trial, we enrolled patients with advanced NSCLC previously treated with cytotoxic chemotherapy. Patients were randomly allocated (11) to receive docetaxel (60 mg/m ) on day 1 or nab-paclitaxel (100 mg/m ) on days 1, 8, and 15 of a 21-day cycle. The primary end point was overall survival (OS) analyzed on an intention-to-treat bas
Like
Comment
Share
